Biologic impact and clinical implication of mTOR inhibition in metastatic breast cancer

Gustavo F. Westin, Cesar A. Perez, Emilie Wang, Stefan Glück

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

The goal of therapy for patients with metastatic breast cancer (MBC) is prolonging life and palliation of symptoms. Thus the preferred approach remains to use, at least initially, non-cytotoxic drugs. In hormone receptor-positive breast cancer the sequential use of single anti-estrogen drugs, e.g. tamoxifen, aromatase inhibitors, and many others is standard, but eventually drug resistance will lead to failure of these compounds and a switch to chemotherapy will be necessary. Reversing resistance to anti-estrogen therapy in MBC is one of the strategies to avoid and delay the use of cytotoxic compounds. The mammalian target of rapamycin (mTOR) has been recently associated with in vitro reversal of drug resistance, including tamoxifen resistance. A number of early clinical studies have confirmed the concept and, more recently, everolimus was successfully tested in a randomized controlled trial in postmenopausal patients who progressed on previous anti-estrogen therapy for MBC. This manuscript will review the biology, preclinical and clinical data including the randomized controlled trial that lead to the approval of everolimus by the US FDA.

Original languageEnglish
Pages (from-to)233-241
Number of pages9
JournalInternational Journal of Biological Markers
Volume28
Issue number3
DOIs
StatePublished - Jul 1 2013
Externally publishedYes

Fingerprint

Sirolimus
Breast Neoplasms
Estrogens
Tamoxifen
Drug Resistance
Pharmaceutical Preparations
Randomized Controlled Trials
Aromatase Inhibitors
Chemotherapy
Therapeutics
Switches
Hormones
Drug Therapy
Everolimus

Keywords

  • Estrogen receptor
  • Estrogen resistance
  • Everolimus
  • Exemestane
  • mTOR protein

ASJC Scopus subject areas

  • Clinical Biochemistry
  • Cancer Research
  • Oncology
  • Pathology and Forensic Medicine

Cite this

Biologic impact and clinical implication of mTOR inhibition in metastatic breast cancer. / Westin, Gustavo F.; Perez, Cesar A.; Wang, Emilie; Glück, Stefan.

In: International Journal of Biological Markers, Vol. 28, No. 3, 01.07.2013, p. 233-241.

Research output: Contribution to journalArticle

Westin, Gustavo F. ; Perez, Cesar A. ; Wang, Emilie ; Glück, Stefan. / Biologic impact and clinical implication of mTOR inhibition in metastatic breast cancer. In: International Journal of Biological Markers. 2013 ; Vol. 28, No. 3. pp. 233-241.
@article{36b96378216144c888c71022ee11f8e7,
title = "Biologic impact and clinical implication of mTOR inhibition in metastatic breast cancer",
abstract = "The goal of therapy for patients with metastatic breast cancer (MBC) is prolonging life and palliation of symptoms. Thus the preferred approach remains to use, at least initially, non-cytotoxic drugs. In hormone receptor-positive breast cancer the sequential use of single anti-estrogen drugs, e.g. tamoxifen, aromatase inhibitors, and many others is standard, but eventually drug resistance will lead to failure of these compounds and a switch to chemotherapy will be necessary. Reversing resistance to anti-estrogen therapy in MBC is one of the strategies to avoid and delay the use of cytotoxic compounds. The mammalian target of rapamycin (mTOR) has been recently associated with in vitro reversal of drug resistance, including tamoxifen resistance. A number of early clinical studies have confirmed the concept and, more recently, everolimus was successfully tested in a randomized controlled trial in postmenopausal patients who progressed on previous anti-estrogen therapy for MBC. This manuscript will review the biology, preclinical and clinical data including the randomized controlled trial that lead to the approval of everolimus by the US FDA.",
keywords = "Estrogen receptor, Estrogen resistance, Everolimus, Exemestane, mTOR protein",
author = "Westin, {Gustavo F.} and Perez, {Cesar A.} and Emilie Wang and Stefan Gl{\"u}ck",
year = "2013",
month = "7",
day = "1",
doi = "10.5301/JBM.5000040",
language = "English",
volume = "28",
pages = "233--241",
journal = "International Journal of Biological Markers",
issn = "0393-6155",
publisher = "Wichtig Publishing",
number = "3",

}

TY - JOUR

T1 - Biologic impact and clinical implication of mTOR inhibition in metastatic breast cancer

AU - Westin, Gustavo F.

AU - Perez, Cesar A.

AU - Wang, Emilie

AU - Glück, Stefan

PY - 2013/7/1

Y1 - 2013/7/1

N2 - The goal of therapy for patients with metastatic breast cancer (MBC) is prolonging life and palliation of symptoms. Thus the preferred approach remains to use, at least initially, non-cytotoxic drugs. In hormone receptor-positive breast cancer the sequential use of single anti-estrogen drugs, e.g. tamoxifen, aromatase inhibitors, and many others is standard, but eventually drug resistance will lead to failure of these compounds and a switch to chemotherapy will be necessary. Reversing resistance to anti-estrogen therapy in MBC is one of the strategies to avoid and delay the use of cytotoxic compounds. The mammalian target of rapamycin (mTOR) has been recently associated with in vitro reversal of drug resistance, including tamoxifen resistance. A number of early clinical studies have confirmed the concept and, more recently, everolimus was successfully tested in a randomized controlled trial in postmenopausal patients who progressed on previous anti-estrogen therapy for MBC. This manuscript will review the biology, preclinical and clinical data including the randomized controlled trial that lead to the approval of everolimus by the US FDA.

AB - The goal of therapy for patients with metastatic breast cancer (MBC) is prolonging life and palliation of symptoms. Thus the preferred approach remains to use, at least initially, non-cytotoxic drugs. In hormone receptor-positive breast cancer the sequential use of single anti-estrogen drugs, e.g. tamoxifen, aromatase inhibitors, and many others is standard, but eventually drug resistance will lead to failure of these compounds and a switch to chemotherapy will be necessary. Reversing resistance to anti-estrogen therapy in MBC is one of the strategies to avoid and delay the use of cytotoxic compounds. The mammalian target of rapamycin (mTOR) has been recently associated with in vitro reversal of drug resistance, including tamoxifen resistance. A number of early clinical studies have confirmed the concept and, more recently, everolimus was successfully tested in a randomized controlled trial in postmenopausal patients who progressed on previous anti-estrogen therapy for MBC. This manuscript will review the biology, preclinical and clinical data including the randomized controlled trial that lead to the approval of everolimus by the US FDA.

KW - Estrogen receptor

KW - Estrogen resistance

KW - Everolimus

KW - Exemestane

KW - mTOR protein

UR - http://www.scopus.com/inward/record.url?scp=84885928981&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84885928981&partnerID=8YFLogxK

U2 - 10.5301/JBM.5000040

DO - 10.5301/JBM.5000040

M3 - Article

VL - 28

SP - 233

EP - 241

JO - International Journal of Biological Markers

JF - International Journal of Biological Markers

SN - 0393-6155

IS - 3

ER -